Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw

Journal of Craniofacial Surgery

Volumn 23, Issue 3, 2012, Pages 784-788

  Cicciù, Marco ^a   Herford, Alan Scott ^b   Juodžbalys, Gintaras ^c   Stoffella, Enrico ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b LOMA LINDA UNIVERSITY   (United States)

^c LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

bisphosphonates; BMP 2 protein; osteonecrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANALGESIA; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; DRUG EFFECT; HUMAN; JAW DISEASE; MULTIMODALITY CANCER THERAPY; OSTEOPOROSIS; POSTOPERATIVE COMPLICATION; TREATMENT OUTCOME; WOUND HEALING;

BONE MORPHOGENETIC PROTEIN 2; COMBINED MODALITY THERAPY; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS; PAIN MANAGEMENT; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; WOUND HEALING;

EID: 84861830328     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/SCS.0b013e31824dbdd4     Document Type: Conference Paper

References (40)

1. Russell G, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
2. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
5. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematol Am Soc Hematol Educ Program 2006;515:356-360
6. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-1327
7. Sarathy AP, Bourgeois SL, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 2005;31:759-763
8. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102
9. Ruggiero S, Woo V, Mehrotra B, et al. Osteonecrosis of the jaws associated with the use of bisphosphonate medications: a report of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:196-197
10. Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med 2004;351:190-192
11. Robinson NA, Yeo JF. BisphosphonatesVa word of caution. Ann Acad Med Singapore 2004;33(4 suppl):48-49
12. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonatesVhistomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160
13. Starck WJ, Epker BN. Failure of osteointergrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Maxillofac Implants 1995;10:74-78
14. Orriss IR, Key ML, Colston KW, et al. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009;106:109-118
15. Roelofs AJ, Jauhiainen M, Mönkkönen H, et al. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP [published online ahead of print November 7, 2008]. Br J Haematol 2009;144:245-250
16. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061
17. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002;8:1080-1084
18. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research 2002;62:6538-6544
19. Dodson TB. CTX and its role in managing patients exposed to oral bisphosphonates [published online ahead of print January 15, 2010]. J Oral Maxillofac Surg 2010;68:487-488; author reply 488-489
20. Marx RE, Cillo JE Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410
21. Maerevoet M Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102
22. Tarassoff P, Hei Y. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:101-102
23. Bone HG, Santora AC. Ten years of alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;351: 191-192
24. Donoghue AM. Bisphosphonates and osteonecrosis: analogy to phossy jaw. Med J Aust 2005;183:163-164
25. Bone HG, Hosking D, Devogelsaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199
26. Nastro E, Musolino C, Allegra A, et al. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer [published online ahead of print December 12, 2006]. Acta Haematol 2007;117:181-187
27. Nastro E, Allegra A, Oteri G, et al. Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonates. J Oral Maxillofac Surg 2009;67:2701-2703
28. Oteri G, Allegra A, Bellomo G, et al. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration [published online ahead of print June 27, 2008]. Cytokine 2008;43:103-104
29. Morag Y, Morag-Hezroni M, Jamadar DA, et al. Bisphosphonate-related osteonecrosis of the jaw: a pictorial review. Radiographics 2009;29:1971-1984
30. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management [published online ahead of print July 31, 2006]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-441
31. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-100
32. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010;39:251-255
33. Nyström E, Ahlqvist J, Legrell PE, et al. Bone graft remodelling and implant success rate in the treatment of the severely resorbed maxilla: a 5-year longitudinal study. Int J Oral Maxillofac Surg 2002;31:158-164
34. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-1119
35. Lundgren S, Nyström E, Nilson H, et al. Bone grafting to the maxillary sinuses, nasal floor and anterior maxilla in the atrophic edentulous maxilla. A two-stage technique. Int J Oral Maxillofac Surg 1997;26:428-434
36. Badros A, Weikel D, SAlama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;20:945-952
37. Wozney J. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992;32:160-167
38. Boyne PJ. Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg 2001;83A:146-150
39. Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 2005;63:1693-1707
40. Herford AS, Boyne PJ, Rawson R, et al. Bone morphogenetic protein-induced repair of the premaxillary cleft. J Oral Maxillofac Surg 2007;65:2136-2141